Lorundrostat shows continued promise against uncontrolled hypertension - report from ACC.25
Luke Laffin on the phase 2b Advance-HTN study of lorundrostat, whose results were reported in a late-breaking clinical trials presentation at the American College of Cardiology’s 2025 Scientific Session.Video: https://medicaldigest.org/scientific-contents/interview:lorundrostat-shows-continued-promise-against-uncontrolled-hypertension